CSL's Financial Results
Please click the link below to view our most recent and historic Full Year and Half Year Financial Results information.
More InformationSearch Results
931 results found-
In fiscal year 2021-2022, CSL invested approximately $1.16 billion in R&D.
https://newsroom.csl.com/2022-11-02-Next-Generation-mRNA,-Gene-Therapy,-Plasma-Products,-Monoclonal-Antibodies,-and-Recent-Acquisitions-and-Collaborations-Highlight-CSL-R-D-Day-2022 -
NEDs Dr Brian McNamee AO Chair and Independent Non-Executive Director Full year Dr Megan Clark AC Independent Non-Executive Director Full year Professor Andrew Cuthbertson AO Independent Non-Executive Director Full year Dr Brian Daniels Independent Non-Executive Director Part year - from 1 December 2024 Ms Carolyn Hewson AO Independent Non-Executive Director Full year Ms Samantha Lewis Independent Non-Executive Director Full year Ms Marie McDonald Independent Non-Executive Director Full year Ms Elaine Sorg Independent Non-Executive Director Part year - from 1 September 2024 Ms Alison Watkins AM Independent Non-Executive Director Full year
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf -
CSL was originally established by the Australian government in As at 30 June 2021, the CSL Group employed over 25,000 full 1916 for the purpose of supplying Australia with vaccines and time equivalents (FTE) and delivered medicines to patients other bacteriological products.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2021.pdf -
CSL’s vision is a sustainable future for our employees, communities, patients and donors, inspired by innovative science and a values-driven culture.
https://www.csl.com/sustainability -
CSL’s Code of Conduct (the Code) sets the standards for how we conduct business in an ethical and transparent way through our commitment to governance and compliance with all applicable laws, regulations and industry standards.
https://www.csl.com/sustainability/governance/ethics-and-transparency -
About the PI Survey The survey was conducted on behalf of CSL Behring between August 4 and September 22, 2021, among 104 PI patients that have ever received immune globulin treatment, including IVIg (n=65), SCIg in glass vials (n=65), and/or SCIg in PFS (n=33).
https://newsroom.csl.com/2024-01-03-CSL-Behring-Announces-Availability-of-Hizentra-R-Immune-Globulin-Subcutaneous-Human-20-Liquid-10g-Prefilled-Syringe -
CSL engages stakeholders and periodically undertakes a formal materiality assessment process to understand our relevant sustainability-related topics.
https://www.csl.com/sustainability/governance/stakeholder-engagement-and-material-topics -
IgA Nephropathy/IgA Vasculitis from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases .
https://newsroom.csl.com/2025-09-26-CSL-Vifor-and-Travere-Therapeutics-Recognize-Updated-KDIGO-Clinical-Practice-Guidelines-for-IgA-Nephropathy -
August 2024 August 2024 CSL held a virtual investor briefing On the same day as announcing June 2025 following the release of its full-year full year results, CSL announced the results, with the briefing materials appointment of Ms Elaine Sorg to released to the ASX on 13 August 2024.
https://www.csl.com/-/media/csl/documents/csl-governance-docs/corporate-governance-statement-2025.pdf